🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07676305
Recruiting Not applicable

6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics

NCT07676305 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-02-11
Last updated
2026-06-30

Condition(s) studied

Type 2 Diabetes

Investigational drug(s) / intervention(s)

Exercise

Exercise: In both groups participants will complete treadmill walking on 3 days per week for 6 weeks. During the first week participants will walk continuously for 21 minutes during each training session which will be increased to 32 minutes per training session for weeks 2-6. In both groups the treadmill speed and grade will be set to elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 min every 10 min based on safety recommendations. The percentage of LOP will progressively increase over the course of the intervention. Weeks 1 and 2 will be completed at 60% LOP, after which pressure will increase by 5% each subsequent week, corresponding to 65%, 70%, 75%, and 80% LOP during weeks 3, 4, 5, and 6, respectively.

Study summary

To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.

Eligibility

Sex
ALL
Min age
19 Years
Max age
64 Years
Healthy volunteers
No
Inclusion Criteria: A. Aged 19-64 years. B. Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0% C. Completing \<150 minutes of moderate-vigorous physical activity per week. Exclusion Criteria: A. Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise. B. Unstable type 2 diabetes medication of the last 3 months C. Absolute contraindications to BFR (i.e., peripheral vascular disease) D. A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions E. A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) F. Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely G. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of British Columbia Okanagan Kelowna British Columbia Recruiting

More University of British Columbia trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07676305 on ClinicalTrials.gov ↗ ← All trials in Canada